Publication year: 2012
Source:World Neurosurgery
Martin Tjahjadi, Ralph König, Christian Rainer Wirtz, Dieter Woischneck, Thomas Kapapa
Objective To examine the influence of cerebral vasospasm on health-related quality of life after subarachnoid haemorrhage. A further objective was to determine how the timing of nimodipine therapy can influence health-related quality of life. Patients and Methods Patients treated between 1998 and 2008 for non-traumatic subarachnoid haemorrhages were sent a standardised questionnaire for the purposes of documenting their health-related quality of life. Initially the patients were divided into two groups: those with and those without cerebral vasospasm following haemorrhage (radiologically confirmed). Secondly, they were differentiated according to four types of treatment for vasospasm: 1. nimodipine since admission (N=179), 2. nimodipine since diagnosis of vasospasm (N=14), 3. no nimodipine/no vasospasm (N=34), 4. no nimodipine despite vasospasm (N=5). Significance was established as p ≤ 0.05. Results Evaluable questionnaires were returned by 236 patients (68% female, mean age 56.35 ± 12.68 years; 32% male, mean age 54.57 ± 12.20 years). Health-related quality of life generally appeared to be impaired. Yet with the exception of the subscale (1 of 8) of physical role (p=0.019), there were no differences between patients with and without vasospasm. Variations in the different treatments revealed significant effects in terms of the component summaries and subscales: physical role and pain, general health, vitality, social functioning, emotional role, mental health and mental component summary (p ≤ 0.04). Conclusion Cerebral vasospasm had little influence on health-related quality of life in our patient population. Health-related quality of life cannot be used as the only argument in favour of treating cerebral vasospasm with nimodipine.
Source:World Neurosurgery
Martin Tjahjadi, Ralph König, Christian Rainer Wirtz, Dieter Woischneck, Thomas Kapapa
Objective To examine the influence of cerebral vasospasm on health-related quality of life after subarachnoid haemorrhage. A further objective was to determine how the timing of nimodipine therapy can influence health-related quality of life. Patients and Methods Patients treated between 1998 and 2008 for non-traumatic subarachnoid haemorrhages were sent a standardised questionnaire for the purposes of documenting their health-related quality of life. Initially the patients were divided into two groups: those with and those without cerebral vasospasm following haemorrhage (radiologically confirmed). Secondly, they were differentiated according to four types of treatment for vasospasm: 1. nimodipine since admission (N=179), 2. nimodipine since diagnosis of vasospasm (N=14), 3. no nimodipine/no vasospasm (N=34), 4. no nimodipine despite vasospasm (N=5). Significance was established as p ≤ 0.05. Results Evaluable questionnaires were returned by 236 patients (68% female, mean age 56.35 ± 12.68 years; 32% male, mean age 54.57 ± 12.20 years). Health-related quality of life generally appeared to be impaired. Yet with the exception of the subscale (1 of 8) of physical role (p=0.019), there were no differences between patients with and without vasospasm. Variations in the different treatments revealed significant effects in terms of the component summaries and subscales: physical role and pain, general health, vitality, social functioning, emotional role, mental health and mental component summary (p ≤ 0.04). Conclusion Cerebral vasospasm had little influence on health-related quality of life in our patient population. Health-related quality of life cannot be used as the only argument in favour of treating cerebral vasospasm with nimodipine.
Sent with MobileRSS HD FREE
No comments:
Post a Comment